Hyperphosphatemia and Cardiovascular Disease.

摘要: Hyperphosphatemia or even serum phosphate levels within the "normal laboratory range" are highly associated with increased cardiovascular disease risk and mortality in general population patients suffering from chronic kidney (CKD). As function declines, rise subsequently induce development of hypertension, vascular calcification, cardiac valvular atherosclerosis, left ventricular hypertrophy myocardial fibrosis by distinct mechanisms. Therefore, is considered as a promising therapeutic target to improve outcome CKD patients. The current strategies based on dietary pharmacological reduction prevent hyperphosphatemia Large randomized clinical trials hard endpoints urgently needed establish causal relationship between excess (CVD) determine if lowering constitutes an effective intervention for prevention treatment CVD.